Surrozen (SRZN) Revenue & Revenue Breakdown
Surrozen Revenue Highlights
00
Surrozen Revenue by Period
Surrozen Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | -100.00% |
2022-12-31 | $12.50M | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | - |
Surrozen Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $4.15M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | -100.00% |
2022-12-31 | $12.50M | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | - |
Surrozen Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
CTMX | CytomX Therapeutics | $101.21M | $33.43M |
SPRO | Spero Therapeutics | $96.73M | $13.47M |
BOLT | Bolt Biotherapeutics | $7.88M | $1.14M |
ASMB | Assembly Biosciences | $7.16M | $6.84M |
KZR | Kezar Life Sciences | $7.00M | - |
KRON | Kronos Bio | $6.29M | $2.37M |
LYRA | Lyra Therapeutics | $1.56M | $195.00K |
UNCY | Unicycive Therapeutics | $675.00K | - |
KROS | Keros Therapeutics | $151.00K | $37.00K |
GOSS | Gossamer Bio | - | $9.48M |
EVLO | Evelo Biosciences | - | - |
TIL | Instil Bio | - | - |
REPL | Replimune Group | - | - |
PCSA | Processa Pharmaceuticals | - | - |
NLTX | Neurogene | - | - |
TPST | Tempest Therapeutics | - | - |
LRMR | Larimar Therapeutics | - | - |
ERYP | PHAXIAM Therapeutics | - | - |
NVCT | Nuvectis Pharma | - | - |
SRZN | Surrozen | - | - |